ERBB2 and breast carcinoma: Two patients were imaged and treated with [68Ga]Ga-NODAGA-THERANOSTTM, the first patient (28 year old female with grade three HER2+ breast cancer and liver metastases) received 472 MBq of radiolabelled peptidomimetics conjugate and highlighted 25 lesions; however, in this same patient, [18F]F-FDG was only able to highlight 12 positive lesions.